Merck's Dr Dave Maraldo outlines 3 principles for placing manufacturing capacity and how end-to-end ADC supply chains could shift platform thinking.
Michael Christel
Advertisement
Michael Christel is the group managing editor of Pharmaceutical Executive, BioPharm International, and Applied Clinical Trials and can be reached at mchristel@mjhlifesciences.com.
Articles by Michael Christel
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
2
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
3
enGene Plans Year-End BLA for Detalimogene in BCG-Unresponsive NMIBC
4
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
5